CONCENTRATIONS |
9 Months Ended |
|---|---|
Sep. 30, 2015 | |
| Notes to Financial Statements | |
| Note 17 - CONCENTRATIONS |
Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.
The Company's revenues earned from sale of products and services for the three months ended September 30, 2015 included 21%, 10%, 29%, 10%, 10% and 10% (aggregate of 90%) from six customers of the Company's total revenues.
The Company's revenues earned from sale of products and services for the nine months ended September 30, 2015 included 14%, 24%, 10% and 16% (aggregate of 64%) from four customers of the Company's total revenues.
The Company's revenues earned from sale of products and services for the three months ended September 30, 2014 included 18%, 48% and 18% (aggregate of 84%) from three customers of the Company's total revenues.
The Company's revenues earned from sale of products and services for the nine months ended September 30, 2014 included 14%, 45% and 28% (aggregate of 87%) from three customers of the Company's total revenues.
Two customers accounted for 49.1% and 19.9% (aggregate of 69%) of the Company's total accounts receivable at September 30, 2015 and three customers accounted for 65%, 16% and 10% of the Company's total accounts receivable at December 31, 2014.
The Company relies on Trinity Rx as its sole supplier of its Naltrexone implant. |